iBio, Inc. said it will undertake a 1-for-10 reverse split of its common stock June 8.
The New York-based biotechnology company's stock will begin trading on the NYSE on a split-adjusted basis starting June 11.
The reverse stock split was authorized by the company's stockholders April 23 while the ratio and effective date were approved by the board May 23.
